Sun Pharma is focusing on deleveraging as it prepares for the $11.75 billion acquisition of Organon, which will be financed through bridge loans expected to be refinanced into long-term debt within an 18-month timeframe. Chief Financial Officer Jayashree Satagopan stated that the company has secured bank funding for the acquisition and plans to run refinancing and integration processes in parallel. The acquisition includes an equity payout of approximately $3.9 billion to Organon shareholders, with the remaining funds sourced from debt and internal accruals. Sun Pharma intends to deploy $2–2.5 billion from its internal cash generation to support the acquisition, while Organon's existing net debt of about $7.6 billion will be consolidated into Sun Pharma's balance sheet. The deal is anticipated to close within 7 to 9 months, pending regulatory and shareholder approvals. Post-acquisition, Sun Pharma aims to prioritize debt reduction, leveraging strong cash flows from both companies, with an annual free cash flow of around $2.5 billion earmarked for this purpose.